OBIO
NASDAQOrchestra BioMed Holdings Inc.
Price$3.94-0.04 (-0.88%)
01:45 PM07:45 PM
News · 26 weeks480%
2025-11-022026-04-26
Mix2690d
- Insider11(42%)
- Other9(35%)
- SEC Filings6(23%)
Latest news
25 items- PRFDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM TherapyAtrioventricular Interval Modulation ("AVIM") Therapy Food and Drug Administration ("FDA") Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension despite medication at increased cardiovascular risk and the specific pacemaker-indicated population being evaluated in the BACKBEAT TrialThe addressable U.S. patient population for AVIM Therapy, based on the indications for use specified in its Breakthrough Device Designations, comprises over 7.7 million adults with hypertension despite medicationBreakthrough Device Designation supports favorable reimbursement pathways, including potential eligibility for New Technology Add-on Payment ("NTAP") and Tr
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Orchestra BioMed Holdings Inc.SCHEDULE 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
- INSIDERLarge owner Rtw Investments, Lp exercised 1,250,032 in-the-money shares at a strike of $0.00 and sold $132 worth of shares (32 units at $4.13) (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- SECSEC Form DEFA14A filed by Orchestra BioMed Holdings Inc.DEFA14A - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
- SECSEC Form DEF 14A filed by Orchestra BioMed Holdings Inc.DEF 14A - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
- PROrchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026Pre-randomization Atrioventricular Interval Modulation Therapy ("AVIM Therapy") set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate average reduction of 13.2 mmHg in office systolic blood pressure ("oSBP")97% of patients experienced an immediate blood pressure reduction of >5 mmHg reduction in oSBP prior to randomizationAVIM Therapy demonstrated the potential to deliver immediate, substantial, and sustained reductions in blood pressure, with evidence of improved diastolic function and reverse cardiac remodelingThe BACKBEAT Global Pivotal Trial, which Orchestra BioMed is actively enrolling as part of a strategic collaboratio
- INSIDERSEC Form 4 filed by Sherman Darren4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERSEC Form 4 filed by Aiello Joshua4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERSEC Form 4 filed by Hochman David P4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDEROfficer Hochman David P bought $42,900 worth of shares (10,000 units at $4.29), increasing direct ownership by 0.93% to 1,086,467 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- PROrchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics' Vivasure acquisition proceeds$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients thro
- SECSEC Form 10-K filed by Orchestra BioMed Holdings Inc.10-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
- PROrchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRTNEW HOPE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced two presentations that will be given at the Technology Heart Failure and Therapeutics ("THT") and Cardiovascular Research Technologies ("CRT") 2026 Meetings highlighting the potential for the Company's Atrioventricular Interval Modulation Therapy ("AVIM Therapy") program in hypertensive heart disease and heart failure patients. Presentation at THT 2026Atrioventricular Interval Modulation
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Orchestra BioMed Holdings Inc.SCHEDULE 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Orchestra BioMed Holdings Inc.SCHEDULE 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
- PROrchestra BioMed to Participate in Upcoming Institutional Investor ConferencesNEW HOPE, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will participate in multiple upcoming institutional investor conferences. Details on the Company's participation appear below: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026 (Boston, MA) Management will participate in a live fireside chat at 9:50am ET on Tuesday, March 3rd and will also host one-on-one meetings with investors. The event will be a
- INSIDERSEC Form 4 filed by Principal Accounting Officer Aiello Joshua4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDEROfficer Sherman Darren was granted 397,000 shares, increasing direct ownership by 47% to 1,237,569 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERChief Financial Officer Taylor Andrew Lawrence was granted 181,000 shares, increasing direct ownership by 40% to 632,493 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDEROfficer Hochman David P was granted 504,000 shares, increasing direct ownership by 88% to 1,076,467 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- SECSEC Form 8-K filed by Orchestra BioMed Holdings Inc.8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
- PROrchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW HOPE, Pa., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on February 12, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 120,000 shares of the Company's common stock to nine newly hired employees. The awards were granted pursuant to the Orchestra Biomed Holdings, Inc. 2025 New Hire Inducement Plan as an inducement material to each new employee entering employment w
- INSIDERDirector Cleary Chris covered exercise/tax liability with 676 shares, decreasing direct ownership by 2% to 36,901 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- SECSEC Form S-8 filed by Orchestra BioMed Holdings Inc.S-8 - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
- SECSEC Form S-8 filed by Orchestra BioMed Holdings Inc.S-8 - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
OBIO FAQ
6 questionsWhere does OBIO stock trade?
Orchestra BioMed Holdings Inc. (OBIO) is listed on NASDAQ.What sector and industry is OBIO in?
Orchestra BioMed Holdings Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.When did Orchestra BioMed Holdings Inc. go public?
Orchestra BioMed Holdings Inc. (OBIO) completed its IPO in 2020.What are analysts saying about OBIO?
Orchestra BioMed Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy with a $1500.00 price target on 2025-12-10. Recent price targets range from $1200.00 to $1600.00.What companies are similar to OBIO?
Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), RGC (Regencell Bioscience Holdings Limited), RLX (RLX Technology Inc.). Compare OBIO side-by-side with any of them on Quantisnow.How can I track OBIO on Quantisnow?
Quantisnow aggregates Orchestra BioMed Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OBIO to receive live email and push alerts on every new disclosure.